Hot on the heels of the official launch at the Asia-Pacific Academy of Ophthalmology Congress in Kuala Lumpur, Eyerising International’s new at-home, red-light therapy device for myopia management, Myproclear, attracted significant attention at CCLSNZ 2023.
The much-anticipated RayOne enhanced monovision (EMV) intraocular lens (IOL) and its latest toric iteration have been launched in New Zealand. Welcoming the move as one of the first surgeons to implant the Rayner IOL in New Zealand, refractive surgeon Dr Dean Corbett said it’s ‘likely to be a game c
A 58-year-old male with no underlying medical history was referred for retinal oedema adjacent to the optic nerve head with cystic changes and a shiny appearance on the overlying retina for the right eye. Unaided visual acuity was 6/9 and 6/6. He was asymptomatic and was incidentally noted to have m
University of Auckland (UoA) researchers are adapting wine-industry technology for a device which they said could prevent deaths from surgical complications. Professor John Windsor, UoA’s Surgical and
A University of Illinois Chicago (UIC) ocular herpes study found blocking a key protein reduced viral reinfection in mice. The UIC team said they found heparanase is upregulated in mouse cornea cells
Join the Tear Film and Ocular Surface Society (TFOS) to learn all about the conclusions and recommendations from its workshop, ‘A Lifestyle Epidemic: Ocular Surface Disease’ from 6-7 May, Eastern
Drs Leo Sheck and Aaron Yap review the latest research on geographic atrophy and diabetic retinopathy
Its first foray into the myopia-control space, Rodenstock has launched the MyCon lens, designed to correct myopia and ensure sharp vision while controlling axial elongation in children aged 6-14 years.
A first-of-its-kind US study has found that ‘dormant’ cone photoreceptors in degenerating retinas of mice are not dormant at all, but continue to function, responding to light and driving retinal activity.
Mitochondrial-stabilising drugs could be key to reversing vision loss in early to intermediate dry age-related macular degeneration (AMD) patients, according to Professor Baruch Kuppermann,
The US Food and Drug Administration (FDA) has granted Priority Review for Aldeyra’s New Drug Application (NDA) for ADX-2191, an investigational drug candidate for the treatment of primary vitreoretina
ONLINE ONLY HOTLINKS: https://www.nzoptics.co.nz/articles/archive/conquering-the-diagnostic-dilemma-of-acanthamoeba-keratitis/
